T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells

Gene Therapy

Volumn 8, Issue 11, 2001, Pages 891-895

  Hombach, A ^a   Muche, J M ^b   Gerken, M ^a   Gellrich, S ^b   Heuser, C ^a   Pohl, C ^c   Sterry, W ^b   Abken, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b St Elisabeth Hospital   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adoptive immunotherapy; CD30; Chimeric receptor; Cutaneous T cell lymphoma

Indexed keywords

CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; RECOMBINANT RECEPTOR;

ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CASE REPORT; COCULTURE; CONTROLLED STUDY; CYTOLYSIS; GENE ISOLATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOMA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR CLONING; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; SKIN CELL; SKIN LYMPHOMA; T CELL LYMPHOMA; T LYMPHOCYTE; TARGET CELL; TUMOR CELL; TUMOR GROWTH;

EID: 0034968389     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301467     Document Type: Article

References (19)

1. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
2. In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes
3. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
4. Can combined T cell- and antibody-based immunotherapy outsmart tumor cells?
5. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors
6. Characterization of circulating T cells specific for tumor associated antigens in melanoma patients
7. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
8. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
9. CD30 is a signal transducing molecule that defines a subset of human activated CD45RO+ T cells
10. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice
11. A chimeric T cell receptor recognizing the CD30 antigen converts cytotoxic T cells to specificity for Hodgkin and Reed Stemberg cells
12. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
13. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma
14. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA
15. T cell activation by recombinant FcεRI γ-chain immune receptors: An extracellular spacer domain impairs antigen dependent T cell activation but not antigen-recognition
16. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes
17. CD30 specific AB1-AB2-AB3 internal image antibody network: Potential use as anti-idiotype vaccine against Hodgkin's lymphoma
18. Characterization of a humanized bispecific monoclonal antibody for cancer therapy
19. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity